Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
189.76
+1.64 (0.87%)
At close: Oct 9, 2026, 4:00 PM EDT
189.96
+0.20 (0.11%)
After-hours: Oct 9, 2026, 7:59 PM EDT
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
40.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
RVMD News
- 2 days ago - Revolution Medicines price target lowered to $264 from $265 at BofA - TheFly
- 3 days ago - RBC would be buyers of Revolution Medicines after FDA docs ‘overreaction’ - TheFly
- 3 days ago - Revolution Medicines selloff ‘overdone and misguided,’ says TD Cowen - TheFly
- 3 days ago - Revolution selloff on FDA review docs should be bought, says Truist - TheFly
- 3 days ago - Revolution trading down after daraxonrasib review docs, says Stifel - TheFly
- 3 days ago - Revolution Medicines price target raised to $259 from $251 at RBC Capital - TheFly
- 4 days ago - Propanc highlights preclinical data for PRP in pancreatic ductal adenocarcinoma - TheFly
- 4 days ago - Revolution Medicines price target raised to $240 from $239 at Truist - TheFly